Bayer Says Xarelto Gets Partial Extension of European Patent

Bayer AG said its blood-thinner Xarelto will be partly patent-protected through January 2026, citing a ruling from the European patent office.

• Patent office reversed a prior decision and will prevent generic competition for the drug when it comes to daily dosing of 10, 15 and 20mg, Bayer says in statement
• Ruling doesn’t affect 2.5mg dosing of the product
• Bayer got about half of its 4.5 billion euros ($5.2 billion) revenue for Xarelto in EMEA region last year, spokesman said in phone interview
• Majority of Xarelto sales in EMEA come from daily dosings of 10, 15 and 20mg, spokesman said
• Decision ...